We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics
Summary
Tiny plastic particles from our environment may be quietly triggering inflammation, weakening protective barriers in our gut and brain, and disrupting normal body signaling—not just polymer buildup, as once assumed. A biotech company called Cythera Bio is proposing a new treatment approach that doesn't try to break down these plastics, but instead works to trap them, stop them from moving through the body, strengthen tissue barriers, and calm the inflammation they cause. This is an early-stage framework rather than a finished treatment, but it points toward future products—both wellness supplements and prescription therapies—aimed at reducing the health
Abstract Microplastics and nanoplastics (MPs/NPs) are increasingly recognized as biologically active environmental particulates capable of interacting with multiple organ systems. While current research has largely focused on environmental detection and polymer degradation, emerging evidence suggests that chronic particulate exposure may contribute to inflammation, barrier dysfunction, immune dysregulation, and altered biological signaling across gastrointestinal, neurological, metabolic, and systemic pathways. Cythera Bio is developing a systems-level therapeutic framework focused on reducing the biological impact of MPs/NPs through interaction-mediated mitigation, inflammatory modulation, and biologically adaptive therapeutic architectures. Rather than relying exclusively on polymer degradation, this framework emphasizes reduction of particle interaction potential through aggregation, sequestration, altered transport dynamics, barrier stabilization, and modulation of downstream inflammatory pathways. The company is pursuing both wellness-oriented exposure support products and FDA-regulated therapeutic programs spanning gastrointestinal disease, neuroinflammation, aging-associated dysfunction, and systemic inflammatory biology. Companion diagnostic and monitoring frameworks may further support exposure characterization and future adaptive therapeutic strategies.